SELP and peripheral arterial disease: The efficacy of the clopidogrel therapy for the PAD study and PAD control groups was confirmed by two other flow cytometric assays, demonstrating clearly reduced ADP-induced integrin αIIbβ3 activation (Supplementary Figure 1B) and P-selectin surface expression as a marker for α-granule release (Supplementary Figure 1C) compared to the other treatment groups with ASA or ASA plus rivaroxaban.